Primary hyperparathyroidism in children

BACKGROUND: Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) with upper-normal or elevated blood calcium levels due to primary thyroid gland pathology. PHPT is a rare pathology in children, with a prevalence of 2–5:100,000 children according to the literature. Due to the non-specificity of clinical manifestations at onset (nausea, vomiting, abdominal pain, emotional lability), the disease may remain undiagnosed for a long time.

AIM: To study the features of the course and molecular genetic basis of primary hyperparathyroidism in children.

MATERIALS AND METHODS: Retrospective observational study of 49 patients diagnosed with primary hyperparathyroidism. All patients underwent a comprehensive laboratory-instrumental and molecular genetic study at the Institute of Pediatric Endocrinology, Endocrinology Research Center of Russia in the period 2014–2022.

RESULTS: The first clinical symptoms of PHPT were noted at the age of 13.8 years [10.6; 1 5.2], among which fatigue, headaches, dyspepsia, lower limb pain, and fractures were the most common. The age of diagnosis was 15.81 years [13.1; 16.8], all children were found to have high levels of PTH, total and ionized calcium, with hypophosphatemia in 93.9% of patients (n=46) and hypercalciuria in 43% (n=21). Five out of 49 patients (10.2%) were found to have ectopy of the thyroid: 3 showed an intrathyroidal location, 2 in the mediastinal region. Molecular genetic study revealed mutations in 32.7% of patients (n=16, CI (21; 47)), mutations in MEN1 being the most frequent (n=11). Pathogenic variants in CDC73 were detected in 3 patients, RET — in 2. Among the operated 39 patients, adenoma of the thyroid was detected in 84.6% of cases (n=33), hyperplasia in 7.7% (n=3), atypical adenoma in 5.1% (n=2), carcinoma in 5.1% of cases (n=2).

CONCLUSION: The paper presents the peculiarities of the course and the results of molecular genetic study of pediatric PHPT. This sample is the largest among those published in the Russian Federation.

1. Mokrysheva N.G., Eremkina A.K., Mirnaia S.S. et al Klinicheskie rekomendatsii po pervichnomu giperparatireozu, kratkaia versiia. Problemy Endokrinologii. 2021;67(4):94-124. https://doi.org/10.14341/probl12801

2. A. A. Khan, D. A. Hanley, R. Rizzoli, J. Bollerslev, and J. E. M. Young, “Primary hyperparathyroidism : review and recommendations on evaluation , diagnosis , and management . A Canadian and international consensus,” Osteoporos. Int., pp. 1–19, 2017, doi: 10.1007/s00198-016-3716-2.

3. A. V Gostimskiy, Z. S. Matveeva, A. F. Romanchishen, I. V Karpatskiy, A. S. Kuzmichev, and S. S. Peredereev, “Osobennosti diagnostiki pervichnogo giperparatireoza u detei ©,” vol. 15, no. 4, pp. 32–37, 2021

4. J. Krupinova et al., “Serum circulating miRNA- ­ 3p as a potential diagnostic biomarker in parathyroid carcinomas : A pilot study,” no. November 2020, pp. 1–10, 2021, doi: 10.1002/edm2.284.

5. A. V. Gostimskii et al., “Pervichnyi g iperparatireoz v detskom vozras te Pr imary hyperpar athyroidism in childhood St . Petersburg State Pediatric Medical University , Ministry of Healthcare of the Russian Federation , Russia,” vol. 8, no. 5, pp. 20–24, 2017, doi: 10.17816/PED8520-24.

6. E. Mamedova and E. V Vasilyev, “Successful Use of Denosumab for Life-Threatening Hypercalcemia in a Pediatric Patient with Primary Hyperparathyroidism,” vol. 117036, 2020, doi: 10.1159/000510625.

7. E. Mamedova, N. Mokrysheva, E. Vasilyev, and V. Petrov, “Primary hyperparathyroidism in young patients in Russia : high frequency of hyperparathyroidism- jaw tumor syndrome,” pp. 557–565, 2017, doi: 10.1530/EC-17-0126.

8. E.A. Orekhova, O.L. Chugunova, S.P. Blokh et al Pervichnyi giperparatireoz kak prichina nefrokaltsinoza i nefrolitiaza u podrostka. Pediatriia im. G.N. Speranskogo. 2023; 102 (4): 186–193. DOI: 10.24110/0031-403X-2023-102-4-186-193.

9. G. Tuli, J. Munarin, D. Tessaris, R. Buganza, P. Matarazzo, and L. De Sanctis, “Case Report ‘ Primary Hyperparathyroidism ( PHPT ) in Children : Two Case Reports and Review of the Literature ,’” vol. 2021, 2021.

10. W. Wang et al., “Primary hyperparathyroidism in Chinese children and adolescents : A single- ­ centre experience at Peking Union Medical College Hospital,” no. August, pp. 865–873, 2017, doi: 10.1111/cen.13453.

11. R. Jamshidi and J. C. Egan, “Seminars in Pediatric Surgery Pediatric parathyroid disease,” Semin. Pediatr. Surg., vol. 29, no. 3, p. 150923, 2020, doi: 10.1016/j.sempedsurg.2020.150923.

12. Gorbacheva A.M., Eremkina A.K., Mokrysheva N.G. Nasledstvennye cindromalnye i nesindromalnye formy pervichnogo giperparatireoza. Problemy Endokrinologii. 2020;66(1):23-34. https://doi.org/10.14341/probl10357

13. F. Cetani, F. Saponaro, S. Borsari, and C. Marcocci, “Familial and Hereditary Forms of Primary Hyperparathyroidism,” vol. 51, pp. 40–51, 2019, doi: 10.1159/000491037.

14. F. Giusti, L. Cavalli, T. Cavalli, and M. L. Brandi, “Hereditary Hyperparathyroidism Syndromes,” J. Clin. Densitom., vol. 16, no. 1, pp. 69–74, 2013, doi: 10.1016/j.jocd.2012.11.003.

15. S. J. Marx and N. Sinaii, “Neonatal Severe Hyperparathyroidism : Novel Insights,” vol. 105, no. April, pp. 1061–1078, 2020, doi: 10.1210/clinem/dgz233.

16. D. Sadacharan et al., “Neonatal Severe Primary Hyperparathyroidism : A Series of Four Cases and their Long ‑ term Management in India,” pp. 196–201, 2020, doi: 10.4103/ijem.IJEM.

17. V. J. Stokes, M. F. Nielsen, F. M. Hannan, and R. V Thakker, “Hypercalcemic Disorders in Children,” vol. 32, no. 11, pp. 2157–2170, 2017, doi: 10.1002/jbmr.3296.

18. J. E. Blau and W. F. Simonds, “Familial Hyperparathyroidism,” vol. 12, no. February, pp. 1–14, 2021, doi: 10.3389/fendo.2021.623667.

19. E. O. Mamedova et al., “Molekuliarno-geneticheskie osobennosti pervichnogo giperparatireoza u patsientov molodogo vozrasta,” 2016, doi: 10.14341/probl20166224-11

20. J. Kollars et al., “Primary Hyperparathyroidism in Pediatric Patients,” vol. 115, no. 4, 2005, doi: 10.1542/peds.2004-0804.

21. Y. El Allali et al., “Presenting features and molecular genetics of primary hyperparathyroidism in the paediatric population,” 2021.

22. O. P. Ryzhkova et al., “Rukovodstvo po interpretatsii dannykh posledovatelnosti DNK cheloveka, poluchennykh metodami massovogo parallelnogo sekvenirovaniia (MPS) (redaktsiia 2018, versiia 2),” pp. 3–23, 2019, doi: 10.25557/2073-7998.2019.02.3-23.

23. S. Richards, N. Aziz, S. Bale, D. Bick, and S. Das, “ACMG Standards and Guidelines Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” vol. 17, no. 5, pp. 405–424, 2015, doi: 10.1038/gim.2015.30.

24. H. Z. Marzouki et al., “Location of Parathyroid Adenomas : 7-Year Experience,” vol. 39, no. 5, pp. 551–554, 2010, doi: 10.2310/7070.2010.090251.

25. S. K. Çetin, “Clinical Profile of Parathyroid Adenoma in Children and Adolescents : A Single-Center Experience,” 2023, doi: 10.5152/TurkArchPediatr.2022.22180.

26. M. E. Flokas, G. Ganieva, A. Grieco, and L. Agdere, “AACE Clinical Case Reports Ectopic Parathyroid Adenoma in an 11-Year-Old Girl : Case Report and Literature Review,” AACE Clin. Case Reports, vol. 7, no. 1, pp. 51–56, 2021, doi: 10.1016/j.aace.2020.11.013.

27. N. G. Mokrysheva, J. A. Krupinova, and I. A. Voronkova, “Okoloshchitovidnye zhelezy : normalnoe razvitie , anatomicheskoe i gistologicheskoe stroenie Parathyroid glands : the normal development , anatomy and histological structure,” vol. 12, no. 4, pp. 178–187, 2018, doi: 10.14341/serg10039.23.

28. A. Manuscript, “NIH Public Access,” vol. 75, no. 9, pp. 425–434, 2013, doi: 10.1016/j.jcma.2012.06.012.Primary.

29. K. Brewer, K. Brewer, J. Costa-guda, and A. Arnold, “Molecular genetic insights into sporadic primary hyperparathyroidism,” vol. 4, 2019.

30. W. F. Simonds, M. D. Branch, and K. Diseases, “HHS Public Access,” pp. 1–16, 2018, doi: 10.1016/j.ecl.2017.01.006.Genetics.

31. A. Dutta et al., “Pediatric Parathyroid Carcinoma : A Case Report and Review of the Literature,” vol. 3, no. March, 2019, doi: 10.1210/js.2019-00081.

32. A. Rahimi et al., “A Pediatric Parathyroid Carcinoma : An Unusual Clinical Presentation and Mini-review,” vol. 19, no. 1, 2021, doi: 10.5812/ijem.110234.Case.

33. F. Jose, A. De Paula, L. Carlos, and C. De Freitas, “Primary Hyperparathyroidism as the First Clinical Manifestation of Multiple Endocrine Neoplasia,” vol. 21, no. 5, pp. 10–13, 2011, doi: 10.1089/thy.2010.0336.

34. H. Dralle, A. Machens, A. Spitschak, K. Lorenz, and B. M. Pu, “Germline RET sequence variation I852M and occult medullary thyroid cancer : harmless polymorphism or causative mutation ?,” pp. 801–805, 2011, doi: 10.1111/j.1365-2265.2011.04158.x.

35. H. Boro, S. Alam, V. Kubihal, S. Khatiwada, S. Kubihal, and S. Agarwal, “Atypical parathyroid adenoma : Severe manifestations in an adolescent girl Nietypowy gruczolak przytarczyc : ciężkie objawy u dorastającej dziewczynki Rajesh Khadgawat,” vol. 28, no. 1, pp. 91–100, 2022.

36. N. G. Mokrysheva, A. K. Eremkina, and K. U. Slashchuk, “Atipicheskaia adenoma okoloshchitovidnoi zhelezy s klinicheski agressivnym techeniem pervichnogo giperparatireoza : nabliudenie iz praktiki Atypical parathyroid adenoma with clinically aggressive course of hyperparathyroidism : clinical case report,” vol. 12, no. 1, pp. 55–63, 2018, doi: 10.14341/serg9587.

37. WHO Classification of Tumor Editional Board. Endocrine and neuroendocrine tumors. Lyon (France): Inrenational Agency for Research on Cancer, 2022. (WHO classification of tumor series, 5th ed.; vol.10). https://publications.iarc.fr.